Matinas BioPharma Holdings (MTNB) Non-Current Assets (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Non-Current Assets data on file, last reported at $3.1 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $3.1 million, down 31.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.1 million (down 31.84% YoY), and the FY2025 annual result was $3.1 million, down 32.13% from the prior year.
• Non-Current Assets declined to $3.1 million in Q1 2026 per MTNB's latest filing, from $3.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $10.7 million in Q1 2022 and troughed at $3.1 million in Q1 2026.
• A 5-year average of $7.8 million and a median of $9.3 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets increased 16.16% in 2022, then slumped 54.26% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $10.3 million in 2022, then fell by 7.06% to $9.6 million in 2023, then sank by 51.72% to $4.6 million in 2024, then plunged by 32.13% to $3.1 million in 2025, then decreased by 2.36% to $3.1 million in 2026.
• Business Quant data shows MTNB's Non-Current Assets at $3.1 million in Q1 2026, $3.1 million in Q4 2025, and $4.0 million in Q3 2025.